Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, has announced their participation in four virtual investor conferences this September. Key events include presentations at the Citi’s 16th Annual BioPharma Virtual Conference on Sept. 8, the Wells Fargo Virtual Healthcare Conference on Sept. 9, a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Sept. 13, and a presentation at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Sept. 30. Live and archived webcasts will be available on Bolt's website.
- None.
- None.
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present a corporate update and conduct meetings with the investment community at four upcoming virtual investor conferences in September:
- Citi’s 16th Annual BioPharma Virtual Conference
Meetings with investors on Wednesday, Sept. 8
- Wells Fargo Virtual Healthcare Conference
Presentation on Thursday, Sept. 9, at 12:30 p.m. PT (3:20 p.m. ET)
- Morgan Stanley 19th Annual Global Healthcare Conference
Fireside chat on Monday, Sept. 13, at 12:30 p.m. PT (3:30 p.m. ET)
- 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Presentation on Thursday, Sept. 30, at 11:00 a.m. PT (2:00 p.m. ET)
A live webcast of the presentations will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1. For more information, visit https://www.boltbio.com/.
Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
kbergman@boltbio.com
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
Maggie Beller or David Schull
Russo Partners, LLC
646-942-5631
maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com
FAQ
What dates will Bolt Biotherapeutics present at virtual investor conferences in September 2021?
What is the Nasdaq ticker symbol for Bolt Biotherapeutics?
Where can I watch the live webcasts of Bolt Biotherapeutics' presentations?
What is the focus of Bolt Biotherapeutics' immuno-oncology agents?
What is the lead candidate for Bolt Biotherapeutics, and what does it target?
